Rima J. Couzi
Distinguished in Breast Cancer

Dr. Rima J. Couzi

Oncology
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
10803 Falls Road, Pavilion III STE 1500, Pavilion III STE 1500, 
Lutherville, MD 
Offers Telehealth

Distinguished in Breast Cancer
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
10803 Falls Road, Pavilion III STE 1500, Pavilion III STE 1500, 
Lutherville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Rima Jean Couzi is a cancer specialist in Towson, Maryland, caring for patients with breast cancer. Dr. Couzi earned her medical degree at the National University of Ireland. She completed residencies at St. Laurence's Hospital/Beaumont Hospitals and Galway Regional in Dublin, as well as Franklin Square Hospital in Baltimore. She performed a fellowship in medical oncology at St. Vincent's Hospital and St. James's Hospital in Dublin, and an additional fellowship in medical oncology at Johns Hopkins Oncology Center in Baltimore. She also earned a master’s degree in clinical epidemiology from the Johns Hopkins Bloomberg School of Public Health. Dr. Couzi joined the Johns Hopkins faculty in 2004. Dr. Couzi is a member of the American Society of Clinical Oncology and the Royal College of Physicians in Ireland. Selected Publications Antonarakis ES, Fradin JM, Petronis JD, Couzi RJ. “Not What It Seems.” Am J Med. 2007;120:408-411 Holdhoff M, Wung PK, Petronis J, Couzi R. “Persistent PET-positive liver lesions after successful chemotherapy in a patient with mediastinal seminoma.” J. Clin Oncol. 2007;25:2482-4. Li S, Couzi RJ, Thomas GH, Friedman AD, Borowitz MJ. “A novel variant three-way translocation of inversion 16 in a case of AML-M4eo following low dose methotrexate therapy.” Cancer Genet Cytogenet. 2001; 125:74-7. Schultz MJ, Tabb RD, Eagan JW, Citron JR, Couzi RJ. “Treating a male breast cancer patient with moderately differentiated, infiltrating ductal cancer of the breast.” Journal of Multidisciplinary Cancer Care. 2009 September – October. Siegelbaum MH, Citron JR, Eagan JW, Couzi RJ. “Treating a patient with Unfavorable-risk prostate cancer.” Journal of Multidisciplinary Cancer Care. 2009; July – August.

Dr. Couzi is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 6 clinical trials in the study of Breast Cancer.

Graduate Institution
Johns Hopkins Bloomberg School Of Public Health, Epidemiology, MHS, 1994
Residency
MedStar Franklin Square Medical Center, Internal Medicine, 1997
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Medical Oncology, 1995
St. Vincent's University Hospital, Internal Medicine & Medical Oncology, 1990
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Arabic
French
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
10803 Falls Road, Pavilion III STE 1500, Pavilion III STE 1500, Lutherville, MD 21093
Call: 410-583-2970

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
View 5 Less Clinical Trials

7 Total Publications

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
Journal: JCO precision oncology
Published: October 11, 2024
View All 7 Publications
Similar Doctors
Antonio C. Wolff
Elite in Breast Cancer
Dr. Antonio C. Wolff
Oncology
Elite in Breast Cancer
Dr. Antonio C. Wolff
Oncology

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

Lutherville, MD 
 (10.1 miles away)
410-583-2970
Languages Spoken:
English, French, Portuguese, Spanish
See accepted insurances
Offers Telehealth

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

Cesar A. Santa
Elite in Breast Cancer
Dr. Cesar A. Santa
Oncology
Elite in Breast Cancer
Dr. Cesar A. Santa
Oncology

Skip Viragh Outpatient Cancer Center

Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. He works as both a primary oncologist and consultant for patients with all types and stages of breast cancer. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy. Dr. Santa is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Claudine J. Isaacs
Elite in Breast Cancer
Dr. Claudine J. Isaacs
Hematology Oncology | Oncology
Elite in Breast Cancer
Dr. Claudine J. Isaacs
Hematology Oncology | Oncology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances

Claudine Isaacs is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Isaacs is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Couzi's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Couzi is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Couzi is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Couzi is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Couzi is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Ovarian Carcinosarcoma
      Dr. Couzi is
      Advanced
      . Learn about Ovarian Carcinosarcoma.
      See more Ovarian Carcinosarcoma experts
    • Sertoli-Leydig Cell Tumor
      Dr. Couzi is
      Advanced
      . Learn about Sertoli-Leydig Cell Tumor.
      See more Sertoli-Leydig Cell Tumor experts
    • Experienced
    • Bone Tumor
      Dr. Couzi is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Breast Cancer in Men
      Dr. Couzi is
      Experienced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Chondrosarcoma
      Dr. Couzi is
      Experienced
      . Learn about Chondrosarcoma.
      See more Chondrosarcoma experts
    • Endometrial Cancer
      Dr. Couzi is
      Experienced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    • Familial Pancreatic Cancer
      Dr. Couzi is
      Experienced
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Follicular Lymphoma
      Dr. Couzi is
      Experienced
      . Learn about Follicular Lymphoma.
      See more Follicular Lymphoma experts
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.